PMID- 17436399
OWN - NLM
STAT- MEDLINE
DCOM- 20070525
LR  - 20181201
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 12
IP  - 1
DP  - 2007 Jan-Mar
TI  - Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by 
      consolidation chemotherapy for unresectable stage III non-small cell lung cancer: 
      preliminary results of a phase II study.
PG  - 33-9
AB  - PURPOSE: To determine the efficacy, toxicity and survival of concurrent therapy 
      with vinorelbine and a platinum compound with radiotherapy (RT), followed by 
      consolidation chemotherapy with the same drugs, for locally advanced non small 
      cell lung cancer (NSCLC). PATIENTS AND METHODS: Fifty-seven patients with stage 
      III NSCLC were included in this phase II study: median age 56 years (range 
      44-71), males / females 49/8, ECOG performance status (PS) 1/2=27/30, stage IIIA/ 
      IIIB 11/46, squamous cell carcinoma 44, adenocarcinoma 7, adenoid cystic 
      carcinoma 1 and large cell carcinoma 5. Treatment consisted of 2 cycles of 
      chemotherapy with vinorelbine and cisplatin or carboplatin, given concurrently 
      with RT, followed by 2-4 more cycles of consolidation chemotherapy with the same 
      drugs. Twenty-two patients received amifostine for radio- and chemoprotection. 
      RESULTS: Grade 3 or 4 toxicities were neutropenia and esophagitis in 19% of the 
      patients each, and gastrointestinal toxicity in 17% of the patients. Of the 55 
      patients evaluable for response, 23.64% achieved complete response (CR) and 40% 
      partial response (PR) (overall response rate 63.64%). Progression-free survival 
      curves showed 1- and 2-year values of 42% and 21%, respectively, and median time 
      to progression 10.5 months. The 1- and 2- year disease-specific survival was 58% 
      and 29%, and the median overall survival 15 months. CONCLUSION: Preliminary 
      analysis indicates that concurrent vinorelbine and a platinum compound with RT 
      followed by consolidation chemotherapy with the same drugs for advanced stage III 
      NSCLC is well tolerated, has considerable activity and positive impact on 
      survival.
FAU - Rusu, P
AU  - Rusu P
AD  - Department of Radiotherapy, Institute of Oncology Prof. Ion Chiricuta, Cluj - 
      Napoca, Romania. petronelarusu@yahoo.com
FAU - Ciuleanu, T E
AU  - Ciuleanu TE
FAU - Cernea, D
AU  - Cernea D
FAU - Pelau, D
AU  - Pelau D
FAU - Gaal, V
AU  - Gaal V
FAU - Cebotaru, C
AU  - Cebotaru C
FAU - Guttman, T
AU  - Guttman T
FAU - Todor, N
AU  - Todor N
FAU - Ghilezan, N
AU  - Ghilezan N
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Radiation-Protective Agents)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - BG3F62OND5 (Carboplatin)
RN  - M487QF2F4V (Amifostine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
MH  - Aged
MH  - Amifostine/therapeutic use
MH  - Antineoplastic Agents, Phytogenic/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Cisplatin/administration & dosage
MH  - Disease-Free Survival
MH  - Drug Administration Schedule
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Patient Compliance
MH  - Radiation-Protective Agents/therapeutic use
MH  - Radiotherapy, Adjuvant
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage/analogs & derivatives
MH  - Vinorelbine
EDAT- 2007/04/17 09:00
MHDA- 2007/05/26 09:00
CRDT- 2007/04/17 09:00
PHST- 2007/04/17 09:00 [pubmed]
PHST- 2007/05/26 09:00 [medline]
PHST- 2007/04/17 09:00 [entrez]
PST - ppublish
SO  - J BUON. 2007 Jan-Mar;12(1):33-9.